17 results on '"Sauer, Tamara"'
Search Results
2. Long-term follow-up of chronic spinal cord stimulation for medically intractable orthostatic tremor
- Author
-
Blahak, Christian, Sauer, Tamara, Baezner, Hansjoerg, Wolf, Marc E., Saryyeva, Assel, Schrader, Christoph, Capelle, Hans-Holger, Hennerici, Michael G., and Krauss, Joachim K.
- Published
- 2016
- Full Text
- View/download PDF
3. Time to treatment with recombinant tissue plasminogen activator and outcome of stroke in clinical practice : retrospective analysis of hospital quality assurance data with comparison with results from randomised clinical trials
- Author
-
Gumbinger, Christoph, Reuter, Björn, Stock, Christian, Sauer, Tamara, Wiethölter, Horst, Bruder, Ingo, Rode, Susanne, Kern, Rolf, Ringleb, Peter, Hennerici, Michael G, and Hacke, Werner
- Published
- 2014
4. Loss of callosal fibre integrity in healthy elderly with age-related white matter changes
- Author
-
Griebe, Martin, Förster, Alex, Wessa, Michèle, Rossmanith, Christina, Bäzner, Hansjörg, Sauer, Tamara, Zohsel, Kathrin, Blahak, Christian, King, Andrea V., Linke, Julia, Hennerici, Michael G., Gass, Achim, and Szabo, Kristina
- Published
- 2011
- Full Text
- View/download PDF
5. Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data
- Author
-
Thomalla, Götz, primary, Boutitie, Florent, additional, Ma, Henry, additional, Koga, Masatoshi, additional, Ringleb, Peter, additional, Schwamm, Lee H, additional, Wu, Ona, additional, Bendszus, Martin, additional, Bladin, Christopher F, additional, Campbell, Bruce C V, additional, Cheng, Bastian, additional, Churilov, Leonid, additional, Ebinger, Martin, additional, Endres, Matthias, additional, Fiebach, Jochen B, additional, Fukuda-Doi, Mayumi, additional, Inoue, Manabu, additional, Kleinig, Timothy J, additional, Latour, Lawrence L, additional, Lemmens, Robin, additional, Levi, Christopher R, additional, Leys, Didier, additional, Miwa, Kaori, additional, Molina, Carlos A, additional, Muir, Keith W, additional, Nighoghossian, Norbert, additional, Parsons, Mark W, additional, Pedraza, Salvador, additional, Schellinger, Peter D, additional, Schwab, Stefan, additional, Simonsen, Claus Z, additional, Song, Shlee S, additional, Thijs, Vincent, additional, Toni, Danilo, additional, Hsu, Chung Y, additional, Wahlgren, Nils, additional, Yamamoto, Haruko, additional, Yassi, Nawaf, additional, Yoshimura, Sohei, additional, Warach, Steven, additional, Hacke, Werner, additional, Toyoda, Kazunori, additional, Donnan, Geoffrey A, additional, Davis, Stephen M, additional, Gerloff, Christian, additional, Acosta, Boris Raul, additional, Aegidius, Karen, additional, Albiker, Christian, additional, Alegiani, Anna, additional, Almendrote, Miriam, additional, Alonso, Angelika, additional, Althaus, Katharina, additional, Amarenco, Pierre, additional, Amiri, Hemasse, additional, Anders, Bettina, additional, Aniculaesei, Adriana, additional, Appleton, Jason, additional, Arenillas, Juan, additional, Back, Christina, additional, Bähr, Christian, additional, Bardutzky, Jürgen, additional, Baronnet-Chauvet, Flore, additional, Bathe-Peters, Rouven, additional, Bayer-Karpinska, Anna, additional, Becerra, Juan L., additional, Beck, Christoph, additional, Belchí Guillamon, Olga, additional, Benoit, Amandine, additional, Berhoune, Nadia, additional, Bindila, Daniela, additional, Birchenall, Julia, additional, Blanc-Lasserre, Karine, additional, Blanco Gonzales, Miguel, additional, Bobinger, Tobias, additional, Bodechtel, Ulf, additional, Bodiguel, Eric, additional, Bojaryn, Urszula, additional, Bonnet, Louise, additional, Bouamra, Benjamin, additional, Bourgeois, Paul, additional, Breuer, Lorenz, additional, Breynaert, Ludovic, additional, Broughton, David, additional, Brouns, Raf, additional, Brugirard, Sébastian, additional, Bruneel, Bart, additional, Buggle, Florian, additional, Cakmak, Serkan, additional, Calleja, Ana, additional, Calvet, David, additional, Carrera, David, additional, Chen, Hsin-Chieh, additional, Cheripelli, Bharath, additional, Cho, Tae-Hee, additional, Choe, Chi-un, additional, Choy, Lillian, additional, Christensen, Hanne, additional, Ciatipis, Mareva, additional, Cloud, Geoffrey, additional, Cogez, Julien, additional, Cortijo, Elisa, additional, Crozier, Sophie, additional, Damgaard, Dorte, additional, Dani, Krishna, additional, De Coene, Beatrijs, additional, De Hollander, Isabel, additional, De Keyser, Jacques, additional, De Klippel, Nina, additional, De Maeseneire, Charlotte, additional, De Smedt, Ann, additional, del Mar Castellanos Rodrigo, Maria, additional, Deltour, Sandrine, additional, Demeestere, Jelle, additional, Derex, Laurent, additional, Desfontaines, Philippe, additional, Dittrich, Ralf, additional, Dixit, Anand, additional, Dobbels, Laurens, additional, Domigo, Valérie, additional, Dorado, Laura, additional, Druart, Charlotte, additional, Dupont, Kristina Hougaard, additional, Dusart, Anne, additional, Dziewas, Rainer, additional, Ebner, Matthias, additional, Edjali-Goujon, Myriam, additional, Eisele, Philipp, additional, El Tawil, Salwa, additional, Elhfnawy, Ahmed, additional, Etexberria, Ana, additional, Evans, Nicholas, additional, Fandler, Simon, additional, Fazekas, Franz, additional, Felix, Sandra, additional, Fiebach, Jochen B., additional, Fiehler, Jens, additional, Filipov, Alexandra, additional, Filipski, Katharina, additional, Fleischmann, Robert, additional, Foerch, Christian, additional, Ford, Ian, additional, Gaenslen, Alexandra, additional, Galinovic, Ivana, additional, Gancedo, Elena Meseguer, additional, Ganeshan, Ramanan, additional, García Esperón, Carlos, additional, Garrido, Alicia, additional, Gattringer, Thomas, additional, Geraghty, Olivia, additional, Geran, Rohat, additional, Gerner, Stefan, additional, Godon-Hardy, Sylvie, additional, Göhler, Jos, additional, Golsari, Amir, additional, Gomis, Meritxell, additional, Gorriz, David, additional, Gramse, Verena, additional, Grau, Laia, additional, Griebe, Martin, additional, Guerrero, Cristina, additional, Guerzoglu, Damla, additional, Guettier, Sophie, additional, Guiraud, Vincent, additional, Gumbinger, Christoph, additional, Gunreben, Ignaz, additional, Haertig, Florian, additional, Hametner, Christian, additional, Hanseeuw, Bernard, additional, Hansen, Andreas, additional, Hansen, Jakob, additional, Harbo, Thomas, additional, Harloff, Andreas, additional, Harmel, Peter, additional, Häusler, Karl Georg, additional, Heinen, Florian, additional, Held, Valentin, additional, Hellwig, Simon, additional, Hemelsoet, Dimitri, additional, Hennerici, Michael, additional, Herm, Juliane, additional, Hermans, Sylvia, additional, Hernández, María, additional, Hervas Vicente, Jose, additional, Hjort, Niels, additional, Hobeanu, Cristina, additional, Hobohm, Carsten, additional, Höfner, Elmar, additional, Hohenbichler, Katharina, additional, Hommel, Marc, additional, Hoppe, Julia, additional, Hornberger, Eva, additional, Hoyer, Carolin, additional, Huang, Xuya, additional, Ipsen, Nils, additional, Isern, Irina, additional, Ispierto, Lourdes, additional, Iversen, Helle, additional, Jeppesen, Lise, additional, Jimenez, Marta, additional, Jungehülsing, Jan, additional, Jüttler, Eric, additional, Kalladka, Dheeraj, additional, Kallmünzer, Bernd, additional, Kar, Arindam, additional, Kellert, Lars, additional, Kemmling, André, additional, Kessler, Tobias, additional, Khan, Usman, additional, Klein, Matthias, additional, Kleinschnitz, Christoph, additional, Klockziem, Matti, additional, Knops, Michael, additional, Koehler, Luzie, additional, Koehrmann, Martin, additional, Kohlfürst, Heinz, additional, Kollmar, Rainer, additional, Kraft, Peter, additional, Krause, Thomas, additional, Kristensen, Bo, additional, Kröber, Jan M., additional, Kurka, Natalia, additional, Ladoux, Alexandre, additional, Laloux, Patrice, additional, Lamy, Catherine, additional, Landrault, Emmanuelle, additional, Lauer, Arne, additional, Lebely, Claire, additional, Leempoel, Jonathan, additional, Lees, Kennedy, additional, Leger, Anne, additional, Legrand, Laurence, additional, Li, Lin, additional, Löbbe, Anna-Mareike, additional, London, Frederic, additional, Lopez-cancio, Elena, additional, Lorenz, Matthias, additional, Louw, Stephen, additional, Lovelock, Caroline, additional, Lozano Sánchez, Manuel, additional, Lucente, Giuseppe, additional, Lückl, Janos, additional, Luna, Alain, additional, Macha, Kosmas, additional, Machet, Alexandre, additional, Mackenrodt, Daniel, additional, Madzar, Dominik, additional, Majoie, Charles, additional, Männer, Anika, additional, Maqueda, Vicky, additional, Marstrand, Jacob, additional, Martinez, Alicia, additional, Marzina, Annika, additional, Mechthouff, Laura, additional, Meden, Per, additional, Meersman, Guy, additional, Meier, Julia, additional, Mellerio, Charles, additional, Menn, Oliver, additional, Meyer, Nadja, additional, Michalski, Dominik, additional, Michels, Peter, additional, Michelsen, Lene, additional, Millán Torne, Monica, additional, Minnerup, Jens, additional, Modrau, Boris, additional, Moeller, Sebastian, additional, Møller, Anette, additional, Morel, Nathalie, additional, Moreton, Fiona, additional, Morin, Ludovic, additional, Moulin, Thierry, additional, Moynihan, Barry, additional, Mueller, Anne K., additional, Muir, Keith W., additional, Mulero, Patricia, additional, Mundiyanapurath, Sibu, additional, Mutzenbach, Johannes, additional, Nagel, Simon, additional, Naggara, Oliver, additional, Nallasivan, Arumugam, additional, Navalpotro, Irene, additional, Nave, Alexander H., additional, Nederkoorn, Paul, additional, Neeb, Lars, additional, Neugebauer, Hermann, additional, Neumann-Haefelin, Tobias, additional, Oberndorfer, Stefan, additional, Opherk, Christian, additional, Oppel, Lorenz, additional, Oppenheim, Catherine, additional, Orthgieß, Johannes, additional, Ostergaard, Leif, additional, Paindeville, Perrine, additional, Palomeras, Ernest, additional, Panitz, Verena, additional, Patel, Bhavni, additional, Peeters, Andre, additional, Peeters, Dirk, additional, Pellisé, Anna, additional, Pelz, Johann, additional, Pereira, Anthony, additional, Pérez de la Ossa, Natalia, additional, Perry, Richard, additional, Petraza, Salvador, additional, Peysson, Stéphane, additional, Pfeilschifter, Waltraud, additional, Pichler, Alexander, additional, Pierskalla, Alexandra, additional, Pledl, Hans-Werner, additional, Poli, Sven, additional, Pomrehn, Katrin, additional, Poulsen, Marika, additional, Prats, Luis, additional, Presas, Silvia, additional, Prohaska, Elisabeth, additional, Puetz, Volker, additional, Puig, Josep, additional, Puig Alcántara, Josep, additional, Purrucker, Jan, additional, Quenardelle, Veronique, additional, Ramachandran, Sankaranarayanan, additional, Raphaelle, Soulliard, additional, Raposo, Nicolas, additional, Reiff, Tilman, additional, Remmers, Michel, additional, Renou, Pauline, additional, Ribitsch, Martin, additional, Richter, Hardy, additional, Ritter, Martin, additional, Ritzenthaler, Thomas, additional, Rodier, Gilles, additional, Rodriguez-Regent, Christine, additional, Rodríguez-Yáñez, Manuel, additional, Roennefarth, Maria, additional, Roffe, Christine, additional, Rosenbaum, Sverre, additional, Rosso, Charlotte, additional, Röther, Joachim, additional, Rozanski, Michal, additional, Ruiz de Morales, Noelia, additional, Russo, Francesca, additional, Rutgers, Matthieu, additional, Sagnier, Sharmilla, additional, Samson, Yves, additional, Sánchez, Josep, additional, Sauer, Tamara, additional, Schäfer, Jan H., additional, Schieber, Simon, additional, Schill, Josef, additional, Schlak, Dennis, additional, Schlemm, Ludwig, additional, Schmidt, Sein, additional, Schonewille, Wouter, additional, Schröder, Julian, additional, Schulz, Andreas, additional, Schurig, Johannes, additional, Schwarting, Sönke, additional, Schwarz, Alexander, additional, Schwarzbach, Christopher, additional, Seidel, Matthias, additional, Seiler, Alexander, additional, Sembill, Jochen, additional, Serena Leal, Joaquin, additional, Shetty, Ashit, additional, Sibon, Igor, additional, Simonsen, Claus Z., additional, Singer, Oliver, additional, Sivagnanaratham, Aravinth, additional, Smets, Ide, additional, Smith, Craig, additional, Soors, Peter, additional, Sprigg, Nikola, additional, Spruegel, Maximilian, additional, Stark, David, additional, Steinert, Susanne, additional, Stösser, Sebastian, additional, Stuermlinger, Markus, additional, Swinnen, Bart, additional, Tamazyan, Ruben, additional, Tembl, Jose, additional, Terceno Izaga, Mikel, additional, Thomalla, Götz, additional, Touze, Emmanuel, additional, Truelsen, Thomas, additional, Turc, Guillaume, additional, Turine, Gaetane, additional, Tütüncü, Serdar, additional, Tyrell, Pippa, additional, Ustrell, Xavier, additional, Vadot, Wilfried, additional, Vallet, Anne-Evelyne, additional, Vallet, Pauline, additional, van den Berg, Lucie, additional, van den Berg, Sophie, additional, van Eendenburg, Cecile, additional, Van Hooff, Robbert-Jan, additional, van Sloten, Isabelle, additional, Vanacker, Peter, additional, Vancaester, Evelien, additional, Vanderdonckt, Patrick, additional, Vandermeeren, Yves, additional, Vanhee, Frederik, additional, Veltkamp, Roland, additional, Vestergaard, Karsten, additional, Viguier, Alain, additional, Vilas, Dolores, additional, Villringer, Kersten, additional, Voget, Dieke, additional, von Schrader, Jörg, additional, von Weitzel, Paul, additional, Warburton, Elisabeth, additional, Weber, Claudia, additional, Weber, Jörg, additional, Wegscheider, Karl, additional, Wegscheider, Mirko, additional, Weimar, Christian, additional, Weinstich, Karin, additional, Weise, Christopher, additional, Weise, Gesa, additional, Willems, Chris, additional, Winder, Klemens, additional, Wittayer, Matthias, additional, Wolf, Marc, additional, Wolf, Martin, additional, Wolff, Valerie, additional, Wollboldt, Christian, additional, Wollenweber, Frank, additional, Wouters, Anke, additional, Yalo, Bertrand, additional, Yger, Marion, additional, Younan, Nadia, additional, Yperzeele, Laetita, additional, Zegarac, Vesna, additional, Zeiner, Pia, additional, Ziemann, Ulf, additional, Zonneveld, Thomas, additional, Zuber, Mathieu, additional, Akutsu, Tsugio, additional, Aoki, Junya, additional, Arakawa, Shuji, additional, Doijiri, Ryosuke, additional, Egashira, Yusuke, additional, Enomoto, Yukiko, additional, Furui, Eisuke, additional, Furuta, Konosuke, additional, Gotoh, Seiji, additional, Hamasaki, Toshimitsu, additional, Hasegawa, Yasuhiro, additional, Hirano, Teryuki, additional, Homma, Kazunari, additional, Ichijyo, Masahiko, additional, Ide, Toshihiro, additional, Igarashi, Shuichi, additional, Iguchi, Yasuyuki, additional, Ihara, Masafumi, additional, Ikenouchi, Hajime, additional, Inoue, Tsuyoshi, additional, Itabashi, Ryo, additional, Ito, Yasuhiro, additional, Iwama, Toru, additional, Kamiyama, Kenji, additional, Kamiyoshi, Shoko, additional, Kanai, Haruka, additional, Kanematsu, Yasuhisa, additional, Kanzawa, Takao, additional, Kimura, Kazumi, additional, Kitayama, Jiro, additional, Kitazono, Takanari, additional, Kondo, Rei, additional, Kudo, Kohsuke, additional, Kusumi, Masayoshi, additional, Kuwahara, Ken, additional, Matsumoto, Shoji, additional, Matsuoka, Hideki, additional, Mihara, Ban, additional, Minematsu, Kazuo, additional, Miura, Ken, additional, Morita, Naomi, additional, Mouri, Wataru, additional, Murata, Kayo, additional, Nagakane, Yoshinari, additional, Nakase, Taizen, additional, Ohara, Hiromi, additional, Ohara, Nobuyuki, additional, Ohnishi, Hideyuki, additional, Ohta, Hajime, additional, Ohtaki, Masafumi, additional, Ohtani, Ryo, additional, Ohtsuki, Toshiho, additional, Ohyama, Hideo, additional, Okada, Takashi, additional, Okada, Yasushi, additional, Osaki, Masato, additional, Sakai, Nobuyuki, additional, Sanbongi, Yoshiki, additional, Sasaki, Naoshi, additional, Sasaki, Makoto, additional, Sato, Shoichiro, additional, Seki, Kenta, additional, Shimizu, Wataru, additional, Shiokawa, Yoshiaki, additional, Sozu, Takashi, additional, Suzuki, Junichiro, additional, Suzuki, Rieko, additional, Takagi, Yasushi, additional, Takizawa, Shunya, additional, Tanahashi, Norio, additional, Tanaka, Eijiro, additional, Tanaka, Ryota, additional, Tateishi, Yohei, additional, Terada, Tomoaki, additional, Terasaki, Tadashi, additional, Todo, Kenichi, additional, Tokunaga, Azusa, additional, Tsujino, Akira, additional, Ueda, Toshihiro, additional, Uesaka, Yoshikazu, additional, Uotani, Mihoko, additional, Urabe, Takao, additional, Watanabe, Masao, additional, Yagita, Yoshiki, additional, Yakushiji, Yusuke, additional, Yasui, Keizo, additional, Yonehara, Toshiro, additional, Yoshimura, Shinichi, additional, Aarnio, K., additional, Alemseged, F., additional, Anderson, C., additional, Ang, T., additional, Archer, M.L., additional, Attia, J., additional, Bailey, P., additional, Balabanski, A., additional, Barber, A., additional, Barber, P.A., additional, Bernhardt, J., additional, Bivard, A., additional, Blacker, D., additional, Bladin, C.F., additional, Brodtmann, A., additional, Cadilhac, D., additional, Campbell, B.C.V., additional, Carey, L., additional, Celestino, S., additional, Chan, L., additional, Chang, W.H., additional, ChangI, A., additional, Chen, C.H., additional, Chen, C.-I., additional, Chen, H.F., additional, Chen, T.C., additional, Chen, W.H., additional, Chen, Y.Y., additional, Cheng, C.A., additional, Cheong, E., additional, Chiou, Y.W., additional, Choi, P.M., additional, Chu, H.J., additional, Chuang, C.S., additional, Chung, T.C., additional, Churilov, L., additional, Clissold, B., additional, Connelly, A., additional, Coote, S., additional, Coulton, B., additional, Cowley, E., additional, Cranefield, J., additional, Curtze, S., additional, D'Este, C., additional, Davis, S.M., additional, Day, S., additional, Desmond, P.M., additional, Dewey, H.M., additional, Ding, C., additional, Donnan, G.A., additional, Drew, R., additional, Eirola, S., additional, Field, D., additional, Frost, T., additional, Garcia-Esperon, C., additional, George, K., additional, Gerraty, R., additional, Grimley, R., additional, Guo, Y.C., additional, Hankey, G., additional, Harvey, J., additional, Ho, S.C., additional, Hogan, K., additional, Howells, D., additional, Hsiao, P.M., additional, Hsu, C.H., additional, Hsu, C.T., additional, Hsu, C.-S., additional, Hsu, J.P., additional, Hsu, Y.D., additional, Hsu, Y.T., additional, Hu, C.J., additional, Huang, C.C., additional, Huang, H.Y., additional, Huang, M.Y., additional, Huang, S.C., additional, Huang, W.S., additional, Jackson, D., additional, Jeng, J.S., additional, Jiang, S.K., additional, Kaauwai, L., additional, Kasari, O., additional, King, J., additional, Kleinig, T.J., additional, Koivu, M., additional, Kolbe, J., additional, Krause, M., additional, Kuan, C.W., additional, Kung, W.L., additional, Kyndt, C., additional, Lau, C.L., additional, Lee, A., additional, Lee, C.Y., additional, Lee, J.T., additional, Lee, Y., additional, Lee, Y.C., additional, Levi, C., additional, Levi, C.R., additional, Lien, L.M., additional, Lim, J.C., additional, Lin, C.C., additional, Lin, C.H., additional, Lin, C.M., additional, Lin, D., additional, Liu, C.H., additional, Liu, J., additional, Lo, Y.C., additional, Loh, P.S., additional, Low, E., additional, Lu, C.H., additional, Lu, C.J., additional, Lu, M.K., additional, Ly, J., additional, Ma, H., additional, Macaulay, L., additional, Macdonnell, R., additional, Mackey, E., additional, Macleod, M., additional, Mahadevan, J., additional, Maxwell, V., additional, McCoy, R., additional, McDonald, A., additional, McModie, S., additional, Meretoja, A., additional, Mishra, S., additional, Mitchell, P.J., additional, Miteff, F., additional, Moore, A., additional, Muller, C., additional, Ng, F., additional, Ng, F.C., additional, Ng, J-L., additional, O'Brian, W., additional, O'Collins, V., additional, Oxley, T.J., additional, Parsons, M.W., additional, Patel, S., additional, Peng, G.S., additional, Pesavento, L., additional, Phan, T., additional, Rodrigues, E., additional, Ross, Z., additional, Sabet, A., additional, Sallaberger, M., additional, Salvaris, P., additional, Shah, D., additional, Sharma, G., additional, Sibolt, G., additional, Simpson, M., additional, Singhal, S., additional, Snow, B., additional, Spratt, N., additional, Stark, R., additional, Sturm, J., additional, Sun, M.C., additional, Sun, Y., additional, Sung, P.S., additional, Sung, Y.F., additional, Suzuki, M., additional, Tan, M., additional, Tang, S.C., additional, Tatlisumak, T., additional, Thijs, V., additional, Tiainen, M., additional, Tsai, C.H., additional, Tsai, C.K., additional, Tsai, C.L., additional, Tsai, H.T., additional, Tsai, L.K., additional, Tseng, C.H., additional, Tseng, L.T., additional, Tsoleridis, J., additional, Tu, H., additional, Tu, H.T-H., additional, Vallat, W., additional, Virta, J., additional, Wang, W.C., additional, Wang, Y.T., additional, Waters, M., additional, Weir, L., additional, Wijeratne, T., additional, Williams, C., additional, Wilson, W., additional, Wong, A.A., additional, Wong, K., additional, Wu, T.Y., additional, Wu, Y.H., additional, Yan, B., additional, Yang, F.C., additional, Yang, Y.W., additional, Yassi, N., additional, Yeh, H.L., additional, Yeh, J.H., additional, Yeh, S.J., additional, Yen, C.H., additional, Young, D., additional, Ysai, C.L., additional, Zhang, W.W., additional, Zhao, H., additional, Zhao, L., additional, Althaus-Knaurer, Katharina, additional, Berrouschot, Jörg, additional, Bluhmki, Erich, additional, Bovi, Paolo, additional, Chatellier, Gilles, additional, Cove, Lynda, additional, Davis, Stephen, additional, Dixit, A., additional, Donnan, Geoffrey, additional, Ehrenkrona, Christina, additional, Eschenfelder, Christoph, additional, Fatar, Marc, additional, Francisco Arenillas, Juan, additional, Gruber, Franz, additional, Kala, Lalit, additional, Kapeller, Peter, additional, Kaste, Markku, additional, Kessler, Christof, additional, Köhrmann, Martin, additional, Laage, Rico, additional, Lees, Kennedy R., additional, Luna Rodriguez, Alain, additional, Mas, Jean-Louis, additional, Mikulik, Robert, additional, Molina, Carlos, additional, Muddegowda, Girish, additional, Muir, Keith, additional, Niederkorn, Kurt, additional, Nuñez, Xavier, additional, Schellinger, Peter, additional, Serena, Joaquin, additional, Sobesky, Jan, additional, Steiner, Thorsten, additional, Svenson, Ann-Sofie, additional, von Kummer, Rüdiger, additional, Wardlaw, Joanna, additional, Betensky, Rebecca A., additional, Boulouis, Gregoire, additional, Carandang, Raphael A., additional, Copen, William A., additional, Cougo, Pedro, additional, Cutting, Shawna, additional, Drake, Kendra, additional, Ford, Andria L., additional, Hallenbeck, John, additional, Harris, Gordon J., additional, Hoesch, Robert, additional, Hsia, Amie, additional, Kase, Carlos, additional, Latour, Lawrence, additional, Lev, Michael H., additional, Muzikansky, Alona, additional, Nagaraja, Nandakumar, additional, Schwamm, Lee H., additional, Searls, Eric, additional, Song, Shlee S., additional, Starkman, Sidney, additional, Yoo, Albert J., additional, and Zand, Ramin, additional
- Published
- 2020
- Full Text
- View/download PDF
6. Predictors and Early Outcome of Hemorrhagic Transformation after Acute Ischemic Stroke
- Author
-
Kablau, Micha, Kreisel, Stefan H., Sauer, Tamara, Binder, Johannes, Szabo, Kristina, Hennerici, Michael G., and Kern, Rolf
- Published
- 2011
- Full Text
- View/download PDF
7. Long-term prognostic value of midregional pro-adrenomedullin and C-terminal pro-endothelin-1 in patients with acute myocardial infarction
- Author
-
Behnes, Michael, Papassotiriou, Jana, Walter, Thomas, Fiedler, Esther, Sauer, Tamara, Lang, Siegfried, Elmas, Elif, Hoffmann, Ursula, Borggrefe, Martin, and Brueckmann, Martina
- Published
- 2008
- Full Text
- View/download PDF
8. Diurnal Variation of Intravenous Thrombolysis Rates for Acute Ischemic Stroke and Associated Quality Performance Parameters
- Author
-
Reuter, Björn, Sauer, Tamara, Gumbinger, Christoph, Bruder, Ingo, Preussler, Stella, Hacke, Werner, Hennerici, Michael G., Ringleb, Peter A., Kern, Rolf, and Stock, Christian
- Subjects
thrombolysis ,Neurology ,daytime ,ischemic stroke ,door-to-imaging time ,Neurology (clinical) ,onset-to-door time ,Neuroscience ,door-to-needle time - Abstract
Introduction Based on data from the Baden-Wuerttemberg stroke registry, we aimed to explore the diurnal variation of acute ischemic stroke (IS) care delivery. Materials and methods 92,530 IS patients were included, of whom 37,471 (40%) presented within an onset-to-door time ≤4.5 h. Daytime was stratified in 3-h time intervals and working vs. non-working hours. Stroke onset and hospital admission time, rate of door-to-neurological examination time ≤30 min, onset-/door-to-imaging time IV thrombolysis (IVT) rates, and onset-/door-to-needle time were determined. Multivariable regression models were used stratified by stroke onset and hospital admission time to assess the relationship between IVT rates, quality performance parameters, and daytime. The time interval 0:00 h to 3:00 h and working hours, respectively, were taken as reference. Results The IVT rate of the whole study population was strongly associated with the sleep–wake cycle. In patients presenting within the 4.5-h time window and potentially eligible for IVT stratification by hospital admission time identified two time intervals with lower IVT rates. First, between 3:01 h and 6:00 h (IVT rate 18%) and likely attributed to in-hospital delays with the lowest diurnal rate of door-to-neurological examination time ≤30 min and the longest door-to-needle time Second, between 6:01 h and 15:00 h (IVT rate 23–25%) compared to the late afternoon and evening hours (IVT rate 27–29%) due to a longer onset-to-imaging time and door-to-imaging time. No evidence for a compromised stroke service during non-working hours was observed. Conclusion The analysis provides evidence that acute IS care is subject to diurnal variation which may affect stroke outcome. An optimization of IS care aiming at constantly high IVT rates over the course of the day therefore appears desirable.
- Published
- 2017
- Full Text
- View/download PDF
9. Access, timing and frequency of very early stroke rehabilitation – insights from the Baden-Wuerttemberg stroke registry
- Author
-
Reuter, Björn, Gumbinger, Christoph, Sauer, Tamara, Wiethölter, Horst, Bruder, Ingo, Diehm, Curt, Ringleb, Peter A., Hacke, Werner, Hennerici, Michael G., and Kern, Rolf
- Subjects
Male ,Rehabilitation ,Clinical Neurology ,Stroke Rehabilitation ,Occupational therapy ,Recovery of Function ,Middle Aged ,Speech Therapy ,Logistic Models ,610 Medical sciences Medicine ,Stroke unit concept ,Multivariate Analysis ,Acute stroke ,Humans ,Female ,Registries ,Physical therapy ,Physical Therapy Modalities ,Research Article ,Aged ,Randomized Controlled Trials as Topic - Abstract
Background: While the precise timing and intensity of very early rehabilitation (VER) after stroke onset is still under discussion, its beneficial effect on functional disability is generally accepted. The recently published randomized controlled AVERT trial indicated that patients with severe stroke might be more susceptible to harmful side effects of VER, which we hypothesized is contrary to current clinical practice. We analyzed the Baden-Wuerttemberg stroke registry to gain insight into the application of VER in acute ischemic stroke (IS) and intracerebral hemorrhage (ICH) in clinical practice. Methods: 99,753 IS patients and 8824 patients with ICH hospitalized from January 2008 to December 2012 were analyzed. Data on the access to physical therapy (PT), occupational therapy (OT), and speech therapy (ST), the time from admission to first contact with a therapist and the average number of therapy sessions during the first 7 days of admission are reported. Multiple logistic regression models adjusted for patient and treatment characteristics were carried out to investigate the influence of VER on clinical outcome. Results: PT was applied in 90/87% (IS/ICH), OT in 63/57%, and ST in 70/65% of the study population. Therapy was mostly initiated within 24 h (PT 87/82%) or 48 h after admission (OT 91/89% and ST 93/90%). Percentages of patients under therapy and also the average number of therapy sessions were highest in those with a discharge modified Rankin Scale score of 2 to 5 and lowest in patients with complete recovery or death during hospitalization. The outcome analyses were fundamentally hindered due to biases by individual decision making regarding the application and frequency of VER. Conclusions: While most patients had access to PT we noticed an undersupply of OT and ST. Only little differences were observed between patients with IS and ICH. The staff decisions for treatment seem to reflect attempts to optimize resources. Patients with either excellent or very unfavorable prognosis were less frequently assigned to VER and, if treated, received a lower average number of therapy sessions. On the contrary, severely disabled patients received VER at high frequency, although potentially harmful according to recent indications from the randomized controlled AVERT trial.
- Published
- 2016
10. Neuroleptic‐like Malignant Syndrome After Battery Depletion in a Patient with Deep Brain Stimulation for Secondary Parkinsonism
- Author
-
Sauer, Tamara, primary, Wolf, Marc E., additional, Blahak, Christian, additional, Capelle, Hans‐Holger, additional, and Krauss, Joachim K., additional
- Published
- 2017
- Full Text
- View/download PDF
11. Restriction of therapy mainly explains lower thrombolysis rates in reduced stroke service levels
- Author
-
Gumbinger, Christoph, primary, Reuter, Björn, additional, Hacke, Werner, additional, Sauer, Tamara, additional, Bruder, Ingo, additional, Diehm, Curt, additional, Wiethölter, Horst, additional, Schoser, Karin, additional, Daffertshofer, Michael, additional, Neumaier, Stephan, additional, Drewitz, Elke, additional, Rode, Susanne, additional, Kern, Rolf, additional, Hennerici, Michael G., additional, Stock, Christian, additional, and Ringleb, Peter, additional
- Published
- 2016
- Full Text
- View/download PDF
12. Intravenous thrombolysis is effective in young adults: results from the Baden-Wuerttemberg stroke registry.
- Author
-
Reuter, Björn, Gumbinger, Christoph, Sauer, Tamara, Wiethölter, Horst, Bruder, Ingo, Diehm, Curt, Ringleb, Peter A., Kern, Rolf, Hacke, Werner, Hennerici, Michael G., Baden-Wuerttemberg, Zweifler, Richard, and Campbell, Bruce
- Subjects
THROMBOLYTIC therapy ,CEREBROVASCULAR disease patients ,STROKE treatment - Abstract
Background: The efficacy of intravenous thrombolysis (IVT) is sufficiently proven in ischemic stroke patients of middle and older age by means of randomized controlled trials and large observational studies. However, data in young stroke patients ≤50 years are still scarce. In this study, we aimed to evaluate the effectiveness and safety of IVT in young adults aged 18-50 years. Data from a consecutive and prospective stroke registry was analyzed that covers a federal state with 10.8 million inhabitants in southwest Germany. Methods: Our analysis comprises 51,735 ischemic stroke patients aged 18-80 years and hospitalized from January 2008 to December 2012. Of these, 4,140 (8%) were aged 18-50 years and 7,529 (15%) underwent IVT. Data on 8,439 patients (16% of the study population) were missing for National Institutes of Health stroke severity score at admission and/or modified Rankin Scale (mRS) at discharge and were excluded from outcome analysis. In sensitivity analysis, patients with incomplete data were also examined. Binary logistic regression models were used adjusted for patient, hospital, and procedural parameters and stratified by age group (18-50 and 51-80 years, subgroup analyses 18-30, 31-40, and 41-50 years) to assess the relationship between IVT and mRS at discharge. Results: IVT appears equally effective in young adults 18-50 years (adjusted odds ratio 1.40, 95% confidence interval 1.12-1.75; p=0.003), compared to patients 51-80 years of age (1.33, 1.23-1.43; p<0.001). Age-stratified analyses suggest an inverse relation of age and effectiveness, which appears to be highest in very young patients 18-30 years of age (2.78, 1.10-7.05; p=0.03). Discussion: Ischemic stroke etiology, vascular dynamics, and recovery in young patients differ from those of middle and older age. The evidence from routine hospital care in Germany indicates that IVT in young stroke patients appears to be at least equally effective as in the elderly. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
13. Vorhofflimmern – Neues in Diagnostik und Therapie
- Author
-
Sauer, Tamara, additional, Anders, Bettina, additional, and Fatar, Marc, additional
- Published
- 2012
- Full Text
- View/download PDF
14. Access, timing and frequency of very early stroke rehabilitation - insights from the Baden-Wuerttemberg stroke registry.
- Author
-
Reuter B, Gumbinger C, Sauer T, Wiethölter H, Bruder I, Diehm C, Ringleb PA, Hacke W, Hennerici MG, and Kern R
- Subjects
- Aged, Female, Humans, Logistic Models, Male, Middle Aged, Multivariate Analysis, Occupational Therapy methods, Physical Therapy Modalities, Randomized Controlled Trials as Topic, Registries, Speech Therapy methods, Recovery of Function, Stroke Rehabilitation methods
- Abstract
Background: While the precise timing and intensity of very early rehabilitation (VER) after stroke onset is still under discussion, its beneficial effect on functional disability is generally accepted. The recently published randomized controlled AVERT trial indicated that patients with severe stroke might be more susceptible to harmful side effects of VER, which we hypothesized is contrary to current clinical practice. We analyzed the Baden-Wuerttemberg stroke registry to gain insight into the application of VER in acute ischemic stroke (IS) and intracerebral hemorrhage (ICH) in clinical practice., Methods: 99,753 IS patients and 8824 patients with ICH hospitalized from January 2008 to December 2012 were analyzed. Data on the access to physical therapy (PT), occupational therapy (OT), and speech therapy (ST), the time from admission to first contact with a therapist and the average number of therapy sessions during the first 7 days of admission are reported. Multiple logistic regression models adjusted for patient and treatment characteristics were carried out to investigate the influence of VER on clinical outcome., Results: PT was applied in 90/87% (IS/ICH), OT in 63/57%, and ST in 70/65% of the study population. Therapy was mostly initiated within 24 h (PT 87/82%) or 48 h after admission (OT 91/89% and ST 93/90%). Percentages of patients under therapy and also the average number of therapy sessions were highest in those with a discharge modified Rankin Scale score of 2 to 5 and lowest in patients with complete recovery or death during hospitalization. The outcome analyses were fundamentally hindered due to biases by individual decision making regarding the application and frequency of VER., Conclusions: While most patients had access to PT we noticed an undersupply of OT and ST. Only little differences were observed between patients with IS and ICH. The staff decisions for treatment seem to reflect attempts to optimize resources. Patients with either excellent or very unfavorable prognosis were less frequently assigned to VER and, if treated, received a lower average number of therapy sessions. On the contrary, severely disabled patients received VER at high frequency, although potentially harmful according to recent indications from the randomized controlled AVERT trial.
- Published
- 2016
- Full Text
- View/download PDF
15. Time to treatment with recombinant tissue plasminogen activator and outcome of stroke in clinical practice: retrospective analysis of hospital quality assurance data with comparison with results from randomised clinical trials.
- Author
-
Gumbinger C, Reuter B, Stock C, Sauer T, Wiethölter H, Bruder I, Rode S, Kern R, Ringleb P, Hennerici MG, and Hacke W
- Subjects
- Aged, Aged, 80 and over, Female, Germany, Hospital Mortality, Humans, Logistic Models, Male, Middle Aged, Outcome Assessment, Health Care methods, Quality Assurance, Health Care, Randomized Controlled Trials as Topic, Recombinant Proteins therapeutic use, Retrospective Studies, Stroke mortality, Time-to-Treatment, Brain Ischemia mortality, Fibrinolytic Agents therapeutic use, Stroke drug therapy, Tissue Plasminogen Activator therapeutic use
- Abstract
Objective: To study the time dependent effectiveness of thrombolytic therapy for acute ischaemic stroke in daily clinical practice., Design: A retrospective cohort study using data from a large scale, comprehensive population based state-wide stroke registry in Germany., Setting: All 148 hospitals involved in acute stroke care in a large state in southwest Germany with 10.4 million inhabitants., Participants: Data from 84,439 patients with acute ischaemic stroke were analysed, 10,263 (12%) were treated with thrombolytic therapy and 74,176 (88%) were not treated., Main Outcome Measures: Primary endpoint was the dichotomised score on a modified Rankin scale at discharge ("favourable outcome" score 0 or 1 or "unfavourable outcome" score 2-6) analysed by binary logistic regression. Patients treated with recombinant tissue plasminogen activator (rtPA) were categorised according to time from onset of stroke to treatment. Analogous analyses were conducted for the association between rtPA treatment of stroke and in-hospital mortality. As a co-primary endpoint the chance of a lower modified Rankin scale score at discharge was analysed by ordinal logistic regression analysis (shift analysis)., Results: After adjustment for characteristics of patients, hospitals, and treatment, rtPA was associated with better outcome in a time dependent pattern. The number needed to treat ranged from 4.5 (within first 1.5 hours after onset; odds ratio 2.49) to 18.0 (up to 4.5 hours; odds ratio 1.26), while mortality did not vary up to 4.5 hours. Patients treated with rtPA beyond 4.5 hours (including mismatch based approaches) showed a significantly better outcome only in dichotomised analysis (odds ratio 1.25, 95% confidence interval 1.01 to 1.55) but the mortality risk was higher (1.45, 1.08 to 1.92)., Conclusion: The effectiveness of thrombolytic therapy in daily clinical practice might be comparable with the effectiveness shown in randomised clinical trials and pooled analysis. Early treatment was associated with favourable outcome in daily clinical practice, which underlines the importance of speeding up the process for thrombolytic therapy in hospital and before admission to achieve shorter time from door to needle and from onset to treatment for thrombolytic therapy., (© Gumbinger et al 2014.)
- Published
- 2014
- Full Text
- View/download PDF
16. Comparison of long-term prognostic value of N-terminal-proBNP and midregional-pro-adrenomedullin in patients with acute myocardial infarction.
- Author
-
Walter T, Brueckmann M, Lang S, Sauer T, Fiedler E, Papassotiriou J, Behnes M, Elmas E, Borggrefe M, and Bertsch T
- Subjects
- Area Under Curve, Blood Chemical Analysis, Female, Hemodynamics, Humans, Male, Middle Aged, Myocardial Infarction blood, Myocardial Infarction physiopathology, Predictive Value of Tests, Prognosis, Prospective Studies, ROC Curve, Adrenomedullin blood, Biomarkers blood, Myocardial Infarction diagnosis, Natriuretic Peptide, Brain blood, Peptide Fragments blood
- Abstract
Background: N-terminal-proBNP (NT-proBNP) and Midregional-pro-Adrenomedullin (MR-proADM) predict mortality of patients with acute myocardial infarction (AMI). Comparison of the prognostic values of NT-proBNP and MR-proADM to predict long-term adverse clinical events (AE) after AMI has not been evaluated yet., Methods: 30 patients with AMI were enrolled into this prospective study. Measurements of NT-proBNP and MR-proADM were performed at initial presentation, two or three days and four months after AMI. Long-term AE defined as recurrent AMI, need for repeated percutaneous transluminal angioplasty or coronary bypass graft surgery, congestive heart failure, cardiopulmonary resuscitation, cardiogenic shock, syncope, and death were documented during a follow-up period of ten months., Results: At initial presentation, NT-proBNP values were significantly higher in patients with AE compared to patients without AE (p < 0.05). The area under the ROC curve (AUC) indicated good predictive performance of NT-proBNP (AUC 0.78, 95% CI 0.59-0.91, p = 0.003) and MR-proADM (AUC 0.71, 95% CI 0.51-0.86, p = 0.046) regarding AE. Comparing both AUC revealed no differences between NT-proBNP and MR-proADM as predictors of AE (p = 0.59). Patients with NT-proBNP levels > or = 370 pg/mL were more likely to suffer from AE than patients with lower levels (relative risk 6.7, 95% CI 1.0-46, p = 0.018). With this cutoff, NT-proBNP could exclude AE with a negative predictive value of 92% being similar to MR-proADM (negative predictive value 76%, relative risk 2.8, 95% CI 1.2-6.9, p = 0.042)., Conclusions: Early measurements of NT-proBNP or MR-proADM during the acute phase of AMI may allow the risk of a long-term AE to be excluded, based on the comparable test characteristics,.
- Published
- 2010
17. Long-term prognostic value of mid-regional pro-adrenomedullin and C-terminal pro-endothelin-1 in patients with acute myocardial infarction.
- Author
-
Behnes M, Papassotiriou J, Walter T, Fiedler E, Sauer T, Lang S, Elmas E, Hoffmann U, Borggrefe M, and Brueckmann M
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Myocardial Infarction blood, Prognosis, Prospective Studies, Adrenomedullin blood, Endothelin-1 blood, Myocardial Infarction diagnosis
- Abstract
Background: Mid-regional pro-adrenomedullin (MR-proADM) and endothelin-1 have been shown to predict mortality of patients with acute myocardial infarction. However, the prognostic value of both biomarkers in predicting long-term clinical events after acute myocardial infarction remains unclear., Methods: In a prospective study, 30 patients suffering from acute ST elevation myocardial infarction or non-ST elevation myocardial infarction were enrolled. Measurements of MR-proADM and CT-pro-endothelin-1 (CT-proET-1) were performed at initial presentation, 2 or 3 days and 4 months after acute myocardial infarction. Long-term clinical events (e.g., recurrent myocardial infarction, percutaneous transluminal coronary angioplasty, aorto-coronary venous bypass or cardiogenic shock) were documented over a period from the 4th until the 10th month., Results: Both MR-proADM and CT-proET-1 were able to differentiate patients with subsequent long-term clinical events (n=11) from those without (n=19). At the time of acute myocardial infarction, median MR-proADM level of the event group was 0.69 nmol/L as compared to 0.59 nmol/L of the no-event group (p=0.036). A difference was still observed after 3 days (event group median 0.66 nmol/L; no-event group median 0.57 nmol/L; p=0.022). Accordingly, median CT-proET-1 level was 72.9 pmol/L in the event group as compared to a median of 54.4 pmol/L in patients in the no-event group (p=0.009) 3 days after acute myocardial infarction. Within the acute phase, patients with MR-proADM levels > or =0.67 nmol/L were 3 times more likely (relative risk 2.8; 95% confidence interval 1.2-6.9; p=0.042) to suffer from a future clinical event. The area under the curve (AUC) was 0.71 (95% confidence interval 0.51-0.86; p=0.046). After 3 days, patients with CT-proET-1 levels > or =57 pmol/L were 6 times more likely (relative risk 5.9; 95% confidence interval 0.9-40.4; p=0.036) to suffer from a future clinical event. The AUC was 0.76 (95% confidence interval 0.55-0.90; p=0.015)., Conclusions: Elevated levels of MR-proADM and CT-proET-1 during the acute phase of myocardial infarction may predict an adverse long-term clinical outcome.
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.